Alisha McArthur Wilkes
Primary Care · Ridgeland, MSNPI 1982080602
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $15,780 of the $17,216 with a category attached, or 91.7%. Eli Lilly accounts for 96.3% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2023 at $13,489 and has fallen 75.7% since, to $3,278 in 2025. Among primary care clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 87 payments — averaging $197.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$17K
- Novo Nordisk$336
- Baxter Healthcare$96
- AstraZeneca$60
- Global Blood Therapeutics, Inc.$31
- Abbott$25
- plus $83 from 5 others
Across 23 payments — averaging $20,668 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$474K
- Regeneron$2K
What the payments were for
- Travel & lodging$15,78092%
- Food & beverage$1,3408%
- Other$961%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 67 | $16,585 |
| Novo Nordisk | 7 | $336 |
| Baxter Healthcare | 1 | $96 |
| AstraZeneca | 4 | $60 |
| Global Blood Therapeutics, Inc. | 2 | $31 |
| Abbott | 1 | $25 |
| Exact Sciences | 1 | $21 |
| Scynexis, Inc. | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| Currax Pharmaceuticals LLC | 1 | $16 |
| Lilly USA, LLC | 1 | $12 |
How this compares
$17,216 in reported general payments places this provider in the 95th percentile of 80 primary care providers in Mississippi.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 11 | $21,469 |
| LinzessLinaclotide | 22 | $17,167 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 19 | $480 |
| Omeprazole | 18 | $329 |
| Promethazine Hcl | 16 | $298 |
| Atorvastatin Calcium | 15 | $209 |
| Montelukast Sodium | 18 | $196 |
| Amlodipine Besylate | 15 | $164 |
| Levothyroxine Sodium | 12 | $157 |
| Gabapentin | 13 | $149 |
| Losartan Potassium | 17 | $147 |
| Pregabalin | 11 | $98 |
| Hydrochlorothiazide | 20 | $96 |
| Fluconazole | 36 | $83 |
| Azithromycin | 15 | $81 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $12 | $21,46911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 80 primary care providers in Mississippi.
Other primary care in Ridgeland
- Orlesha BishopRidgeland$2K
- Katrina BlackardSouthaven$14K
- Sarah HarringtonTupelo$11K
- Julie HarperNewhebron$10K
- Hannah IvisonJackson$10K
- Irene WilsonSouthaven$4K
- Mary EatonTupelo$4K
- Tanya SandersonTupelo$3K
- Amanda EllisKosciusko$3K
- Charity MilamSouthaven$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.